Kraj: Kanada
Język: angielski
Źródło: Health Canada
ENALAPRIL SODIUM; HYDROCHLOROTHIAZIDE
FROSST A DIVISION OF MERCK CANADA INC
C09BA02
ENALAPRIL AND DIURETICS
8MG; 25MG
TABLET
ENALAPRIL SODIUM 8MG; HYDROCHLOROTHIAZIDE 25MG
ORAL
28
Prescription
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
Active ingredient group (AIG) number: 0252326001; AHFS:
CANCELLED PRE MARKET
2016-05-05
_ENALAPRIL/HCTZ (enalapril and hydrochlorothiazide tablets) _ _Page 1 of 44_ PRODUCT MONOGRAPH PR ENALAPRIL/HCTZ (enalapril and hydrochlorothiazide tablets) 10 mg/25 mg Each tablet is made with 10 mg of enalapril maleate that appears as 8 mg of enalapril sodium in the tablet and 25 mg of hydrochlorothiazide. Angiotensin Converting Enzyme Inhibitor / Diuretic FROSST, A DIVISION OF MERCK CANADA INC Date of Revision: 16750 route Transcanadienne March 21, 2016 Kirkland, QC Canada H9H 4M7 SUBMISSION CONTROL NO: 192763 _ENALAPRIL/HCTZ (enalapril and hydrochlorothiazide tablets) _ _Page 2 of 44_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ..................................................................................................10 DRUG INTERACTIONS ..................................................................................................14 DOSAGE AND ADMINISTRATION ..............................................................................19 OVERDOSAGE ................................................................................................................20 ACTION AND CLINICAL PHARMACOLOGY ............................................................21 STORAGE AND STABILITY ..........................................................................................25 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................25 PART II: SCIENTIFIC INFORMATION ...............................................................................26 PHARMACEUTI Przeczytaj cały dokument